Immuneering (IMRX) Total Current Liabilities (2020 - 2026)

Immuneering's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 2.62% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $5.0 million, a 2.62% decrease from a year earlier, with the FY2025 full-year figure at $10.1 million, up 34.25% from the prior year.
• Total Current Liabilities declined to $5.0 million in Q1 2026 per IMRX's latest filing, from $10.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $10.1 million in Q4 2025 and bottomed at $3.7 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $6.8 million (2024), against an average of $6.5 million.
• Biggest YoY gain for Total Current Liabilities was 50.41% in 2023; the steepest drop was 22.51% in 2023.
• Year by year, Total Current Liabilities stood at $8.1 million in 2022, then declined by 2.59% to $7.8 million in 2023, then decreased by 4.36% to $7.5 million in 2024, then surged by 34.25% to $10.1 million in 2025, then tumbled by 50.62% to $5.0 million in 2026.
• Per Business Quant, the three latest IMRX Total Current Liabilities figures stand at $5.0 million (Q1 2026), $10.1 million (Q4 2025), and $9.5 million (Q3 2025).